DRKS00031316尚未招募3 期
PET-guided Radiosurgery of Oligometastatic Cancer - PETOC
Städtisches Klinikum Dessau0 个研究点目标入组 198 人开始时间: 2023年3月2日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one(—)
- 性别
- All
入选标准
- •ICD-10: C00-25, C30-34(NSCLC only), C37, C39, C44-45, C48, C50 (hormone-resistant only), C51-58, C60-61 (castration-resistant only), C63-69, C73-74, and C80
- •oligometastatic disease with =5 extracranial lesions and =3 intrecebral lesions wihtout presious treatment, after relapse after complete remission or partial remission
- •patient qualifies for cytotoxic systemic therapy
- •normal blood counts (Hb>8g/dl, ANC>1500/mm³, thrombocytes >100 000/mm³)
- •normal liver function tests (ASAT/ALAT/AP=2.5*ULN), if liver metastatic and to be treated: <5*ULN
- •Bilirubin <1,5*ULN
- •Creatinin clearance (Cockroft-Gault) > 50 ml/min
- •ability to understand research protocol and willing to comply with reassessments and follow-ups
- •consent to have the patient’s case re-discussed in interdisciplinary tumor boards.
- •negative pregnancy test for female patients aged <50 yrs.
- •if sexually active, ability to use pregnancy prevention methods until 12 months after ending chemotherapy.
- •male patients restrain from fostering a child until 12 months after last chemotherapy
排除标准
- •Extragonadal germ cell tumor
- •Tumor or carcinoma with neuroendocrine features
- •Peritoneal carcinomatosis
- •Hormone-sensitive breast cancer
- •Hormone-sensitive prostate cancer
- •Chorioncarcinoma
- •Hematooncological neoplasia
- •Chemotherapy within the last three months
- •Age = 18 yrs.
- •previous radiotherapy to at least one of the areas currently presenting with oligometastatic disease, exceptions are brain metastasis, and metastasis with compression of the spinal cord
- •pregnancy or lactation
- •patients not compliant with birth control measurements
- •previous or ongoing abuse of medical substances, drugs, or alcohol
- •non-compliance in respect of protocol requirements and follow-ups
- •uncontrolled physical or mental disabilities
- •-including instable angina
- •-cardiac ischemia within the last 3 months
- •-active/treated neurological/psychiatric diagnosis incl. dementia/seizures
- •- active, not controlled infectious disease or bacteremia
- •patients with a history of previous malignant disease, except successfully treated basal cell cancer of the skin or carcinoma-in-situ of the uterine cervix.
研究者
相似试验
已完成
不适用
Stereotactic Radiosurgery for limited brain metastasis using different techiniques, Helical Tomotherapy, Volumetric Modulated Arc Therapy and Cone-based Linac radiosurgeryPatients with known primary cancer who develop limited brain metastasis (less than 4 lesions) and received stereotactic radiosurgery will be enrolled to this studystereotactic radiosurgery,Helical Tomotherapy (HT),Volumetric Arc Therapy (VMAT),Cone-based Linac radiosurgery (cone-based)TCTR20200803006Faculty of Medicine, Chiang Mai University21
招募中
2 期
Stereotactic Radiotherapy for Metastasis to the Lunglung malignancy100386661002910710038737lung cancerNL-OMON35375Erasmus MC, Universitair Medisch Centrum Rotterdam30
已完成
不适用
Positron emission tomography (PET) guided therapy of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with or without high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT)Diffuse large B-cell lymphomaJPRN-UMIN000004420Japan Study Group for Cell Therapy and Transplantation68
进行中(未招募)
不适用
Radio-controlled Surgery RGS in the cancer of the rectum clinical study of feasibility to improve the treatment and prognosis - NDcarcinoma of the rectumMedDRA version: 8.1Level: PTClassification code 10038038Term: Rectal cancerEUCTR2006-001499-18-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI30
进行中(未招募)
1 期
Radiotherapy of multiple brain metastases using AGuIX® gadolinium-chelated polysiloxane based nanoparticles: a prospective randomized phase II clinical trial.EUCTR2018-001879-20-FRGrenoble Alps University Hospital100
